Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout. However, if they fail, that may mean the end of the road for these companies. Here is a list of promising biotechs priced under $10 that could offer a huge return on investment in the coming months.Actinium Pharmaceuticals (ATNM)Source: ShutterstockActinium Pharmaceuticals (NYSEMKT:ATNM) is a biotech working on targe ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Actinium Pharmaceuticals (ATNM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.Actinium Pharmaceuticals is a member of our Medical group, which includes 1042 different companies and currently sits at #6 in the ...

PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence the Acute Myeloid Leukemia Market size is estimated at USD 1.83 billion in 2024, and is expected to reach USD 2.97 billion by 2029, growing at a CAGR of 10.15% during the forecast period (2024-2029). The report said: "Key factors propelling the growth of this market are the high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biolo ...

PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally develop into red blood cells, white blood cells, and platelets. In AML, these abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells. According to Global Market Insights the Acute ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the companies developing innovative solutions, featuring Actinium Pharmaceuticals, Inc. (NYSE American: ATNM). Actinium is a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiot ...

-  Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive Iomab-B (hazard ratio=0.23, p=0.0002) in the Phase 3 SIERRA Trial-  Long-term efficacy results in patients with active relapsed or refractory acute myeloid leukemia also observed in the SIERRA trialNEW YORK, June 14, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Comp ...

- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia - Actimab-A + CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access and improved survival outcomes in high-risk patients including TP53+ and venetoclax treated patients - SNMMI oral presentation highlighted dosimetry results and safety data supporting this novel radiotherapy combination NEW YORK, June 11, 2 ...

In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed. The markets didn’t wait to see if the company can execute the big plans. A good example is Plug Power (NASDAQ:PLUG) stock.Biotech stocks are among the favorite targets during a meme stock rally. This holds particularly true for biotech companies that are still in the process of commercializing various molecular entities. Any positive ...

-  KOL and principal investigator, Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern to join Actinium management on the webinar -  Webinar to be held on Monday, May 20th at 8:00 AM ET NEW YORK, May 15, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced it will host a KOL webinar on M ...

syahrir maulana Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is a late-stage biopharmaceutical company focused on developing radiotherapies for Acute Myeloid Leukemia [AML] patients who have not responded to standard treatments. The firm's leading product candidates are Iomab-B and Actimab-A, which use radiation targeted to leukemia-related antigens to kill cancer without affecting healthy cells, presenting an enhanced treatment efficacy with fewer adverse effects. Iomab-B demonstrated promising phase 3 resul ...